Biochem Immunosystems Inc.

Biochem Pharma Inc.

Iaf Biochem International, Inc.

Martial Lacroix

Gervais Dionne

Maan Zrein

Francesco Bellini

There is provided cyclic peptides of the general formula

Synthetic peptides and mixtures thereof for detecting HIV antibodies

This invention relates to novel peptides and mixtures thereof useful for detecting HCV infections. These peptides are also useful as active ingredients in vaccines against HCV infection.

Peptides and mixtures thereof for detecting antibodies to hepatitis C

This invention discloses linear and cyclic peptides of the E1 and E2 glycoproteins of the rubella virus. These peptides and analogues, mixtures and combinations of them are useful in detecting and quantifying antibodies raised against the rubella virus. They are also useful in raising antibodies to the rubella virus for use in the diagnosis of and protection against rubella viral infections.

Peptides, analogues and mixtures thereof for detecting and eliciting

This invention relates to novel linear peptides and mixtures and chemical combinations thereof useful for detecting and quantifying HTLV-I and HTLV-II infections. These peptides are also useful in vaccines against HTLV-I and HTLV-II vital infections.

Peptides and analogues and mixtures thereof for detecting antibodies to

Linear and cyclic peptides of the E1 and C protein of the rubella virus are disclosed. These peptides and analogues, are useful in detecting and quantifying antibodies raised against the rubella virus. They are also useful in raising antibodies to the rubella virus for use in the diagnosis of and protection against rubella viral infections.

Peptides and analogues and mixtures thereof for detecting and eliciting

There is provided cyclic peptides of the general formulae: ##STR1## wherein x represents an amino acid sequence from position 585 to 604 (gp41-HIV-1) such amino acid sequences being characterized by at least one of a lysine at position 586 or a lysine at both positions 585 and 586; x.sup.2 represents an amino acid sequence from position 585 to 604 (gp41-HIV-1); y represents an amino acid sequence from position 612 to 629 (gp41-HIV-1); e and f represent one or more epitopes; and a and b represent the amino and carboxy terminals, respectively, as well as substituents which are effective to make the peptide more useful as an immunodiagnositc reagent. Peptides of formula III have one or both of e and f present. There is also provided peptides of the general formulae: ##STR2## wherein x.sup.1 represents an amino acid sequence from position 577 to 596 (gp36-HIV-2) such amino acid sequences being characterized by at least one of a lysine at position 578 or a lysine at both positions 577 and 578; x.sup.3 represents an amino acid sequence from position 577 to 596 (gp36-HIV-2); y.sup.1 represents an amino acid sequence from position 604 to 613 (gp36-HIV-2); e and f represents one or more epitopes; and a and b are as defined above. Peptides of formula IV have one or both of e and f present. These cyclic peptides alone or in admixture with other peptides are particularly useful in detecting HIV-1 and HIV-2 antibodies in analytes and sera.

Linear and cyclic peptides of the E1 and C protein of the rubella virus are disclosed. These peptides and analogues, mixtures and combinations of them are useful in detecting and quantifying antibodies raised against the rubella virus. They are also useful in raising antibodies to the rubella virus for use in the diagnosis of and protection against rubella viral infections.

Growing community of inventors

Brossard, Canada

Martial Lacroix